We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Optimizing Starting Material Quality for Cellular Therapeutics

Article   Aug 03, 2018 | by Dominic Clarke, PhD and Marie Aragon, RN, BSN. HemaCare Corporation

 
Optimizing Starting Material Quality for Cellular Therapeutics

Credit: Terumo BCT

 
 
Advertisement
 

RELATED ARTICLES

The Coronavirus Outbreak

Article

On December 31, 2019, the first cases of a novel coronavirus were identified in Wuhan City, Hubei Province, China. Here, we curate a collection of news and content related to the outbreak.

READ MORE

How To Expedite Drug Development by Waiving Certain Clinical Trials

Article

The COVID-19 pandemic has caused numerous obstacles for clinical research across the world. Widespread movement restrictions, a diversion of healthcare personnel to the frontline and a compromised ability to ensure participant safety are examples of the many challenges faced by the pharmaceutical industry. But how can today’s pharma industry make progress and still get products to the market in the face of such long-term disruption? Is it possible to eliminate the need for human trials in some cases?

READ MORE

Urinary DNA Adductomics: The Next Generation of Omics Technology

Article

What are DNA adducts? How can we measure them in a non-invasive manner and what can they teach us about human health and disease? This article by Marcus Cooke from the University of South Florida explains all.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Cell Science Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE